Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of. | June 15, 2023
INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study
Theindianawaaz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theindianawaaz.com Daily Mail and Mail on Sunday newspapers.